Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture

Juan M. Jimenez-Andrade, Carl D. Martin, Nathan J. Koewler, Katie T. Freeman, Lucy J. Sullivan, Kyle G. Halvorson, Christina M. Barthold, Christopher M. Peters, Ryan J. Buus, Joseph R. Ghilardi, Jack L. Lewis, Michael A. Kuskowski, Patrick W Mantyh

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Current therapies to treat skeletal fracture pain are extremely limited. Some non-steroidal anti-inflammatory drugs have been shown to inhibit bone healing and opiates induce cognitive dysfunction and respiratory depression which are especially problematic in the elderly suffering from osteoporotic fractures. In the present report, we developed a closed femur fracture pain model in the mouse where skeletal pain behaviors such as flinching and guarding of the fractured limb are reversed by 10 mg/kg morphine. Using this model we showed that the administration of a monoclonal antibody against nerve growth factor (anti-NGF) reduced fracture-induced pain-related behaviors by over 50%. Treatment with anti-NGF reduced c-Fos and dynorphin up-regulation in the spinal cord at day 2 post-fracture. However, anti-NGF treatment did not reduce p-ERK and c-Fos expression at 20 and 90 min, respectively, following fracture. This suggests NGF is involved in maintenance but not the acute generation of fracture pain. Anti-NGF therapy did not inhibit bone healing as measured by callus formation, bridging of the fracture site or mechanical strength of the bone. As the anti-NGF antibody does not appreciably cross the blood-brain barrier, the present data suggest that the anti-hyperalgesic action of anti-NGF therapy results from blockade of activation and/or sensitization of the CGRP/trkA positive fibers that normally constitute the majority of sensory fibers that innervate the bone. These results demonstrate that NGF plays a significant role in driving fracture pain and that NGF sequestering therapies may be efficacious in attenuating this pain.

Original languageEnglish (US)
Pages (from-to)183-196
Number of pages14
JournalPain
Volume133
Issue number1-3
DOIs
StatePublished - Dec 15 2007
Externally publishedYes

Fingerprint

Nerve Growth Factor
Pain
Antibodies
Bone and Bones
Therapeutics
Opiate Alkaloids
Closed Fractures
Dynorphins
Osteoporotic Fractures
Bony Callus
Blood-Brain Barrier
Psychological Stress
Respiratory Insufficiency
Femur
Morphine
Spinal Cord
Anti-Inflammatory Agents
Up-Regulation
Extremities
Monoclonal Antibodies

Keywords

  • Bone
  • Monoclonal antibody therapy
  • Nociception
  • Non-malignant skeletal pain
  • Periosteum

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology
  • Neuroscience(all)
  • Pharmacology
  • Clinical Psychology

Cite this

Jimenez-Andrade, J. M., Martin, C. D., Koewler, N. J., Freeman, K. T., Sullivan, L. J., Halvorson, K. G., ... Mantyh, P. W. (2007). Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture. Pain, 133(1-3), 183-196. https://doi.org/10.1016/j.pain.2007.06.016

Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture. / Jimenez-Andrade, Juan M.; Martin, Carl D.; Koewler, Nathan J.; Freeman, Katie T.; Sullivan, Lucy J.; Halvorson, Kyle G.; Barthold, Christina M.; Peters, Christopher M.; Buus, Ryan J.; Ghilardi, Joseph R.; Lewis, Jack L.; Kuskowski, Michael A.; Mantyh, Patrick W.

In: Pain, Vol. 133, No. 1-3, 15.12.2007, p. 183-196.

Research output: Contribution to journalArticle

Jimenez-Andrade, JM, Martin, CD, Koewler, NJ, Freeman, KT, Sullivan, LJ, Halvorson, KG, Barthold, CM, Peters, CM, Buus, RJ, Ghilardi, JR, Lewis, JL, Kuskowski, MA & Mantyh, PW 2007, 'Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture', Pain, vol. 133, no. 1-3, pp. 183-196. https://doi.org/10.1016/j.pain.2007.06.016
Jimenez-Andrade JM, Martin CD, Koewler NJ, Freeman KT, Sullivan LJ, Halvorson KG et al. Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture. Pain. 2007 Dec 15;133(1-3):183-196. https://doi.org/10.1016/j.pain.2007.06.016
Jimenez-Andrade, Juan M. ; Martin, Carl D. ; Koewler, Nathan J. ; Freeman, Katie T. ; Sullivan, Lucy J. ; Halvorson, Kyle G. ; Barthold, Christina M. ; Peters, Christopher M. ; Buus, Ryan J. ; Ghilardi, Joseph R. ; Lewis, Jack L. ; Kuskowski, Michael A. ; Mantyh, Patrick W. / Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture. In: Pain. 2007 ; Vol. 133, No. 1-3. pp. 183-196.
@article{95634ab32e9b418cb94758ae5dc7266f,
title = "Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture",
abstract = "Current therapies to treat skeletal fracture pain are extremely limited. Some non-steroidal anti-inflammatory drugs have been shown to inhibit bone healing and opiates induce cognitive dysfunction and respiratory depression which are especially problematic in the elderly suffering from osteoporotic fractures. In the present report, we developed a closed femur fracture pain model in the mouse where skeletal pain behaviors such as flinching and guarding of the fractured limb are reversed by 10 mg/kg morphine. Using this model we showed that the administration of a monoclonal antibody against nerve growth factor (anti-NGF) reduced fracture-induced pain-related behaviors by over 50{\%}. Treatment with anti-NGF reduced c-Fos and dynorphin up-regulation in the spinal cord at day 2 post-fracture. However, anti-NGF treatment did not reduce p-ERK and c-Fos expression at 20 and 90 min, respectively, following fracture. This suggests NGF is involved in maintenance but not the acute generation of fracture pain. Anti-NGF therapy did not inhibit bone healing as measured by callus formation, bridging of the fracture site or mechanical strength of the bone. As the anti-NGF antibody does not appreciably cross the blood-brain barrier, the present data suggest that the anti-hyperalgesic action of anti-NGF therapy results from blockade of activation and/or sensitization of the CGRP/trkA positive fibers that normally constitute the majority of sensory fibers that innervate the bone. These results demonstrate that NGF plays a significant role in driving fracture pain and that NGF sequestering therapies may be efficacious in attenuating this pain.",
keywords = "Bone, Monoclonal antibody therapy, Nociception, Non-malignant skeletal pain, Periosteum",
author = "Jimenez-Andrade, {Juan M.} and Martin, {Carl D.} and Koewler, {Nathan J.} and Freeman, {Katie T.} and Sullivan, {Lucy J.} and Halvorson, {Kyle G.} and Barthold, {Christina M.} and Peters, {Christopher M.} and Buus, {Ryan J.} and Ghilardi, {Joseph R.} and Lewis, {Jack L.} and Kuskowski, {Michael A.} and Mantyh, {Patrick W}",
year = "2007",
month = "12",
day = "15",
doi = "10.1016/j.pain.2007.06.016",
language = "English (US)",
volume = "133",
pages = "183--196",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture

AU - Jimenez-Andrade, Juan M.

AU - Martin, Carl D.

AU - Koewler, Nathan J.

AU - Freeman, Katie T.

AU - Sullivan, Lucy J.

AU - Halvorson, Kyle G.

AU - Barthold, Christina M.

AU - Peters, Christopher M.

AU - Buus, Ryan J.

AU - Ghilardi, Joseph R.

AU - Lewis, Jack L.

AU - Kuskowski, Michael A.

AU - Mantyh, Patrick W

PY - 2007/12/15

Y1 - 2007/12/15

N2 - Current therapies to treat skeletal fracture pain are extremely limited. Some non-steroidal anti-inflammatory drugs have been shown to inhibit bone healing and opiates induce cognitive dysfunction and respiratory depression which are especially problematic in the elderly suffering from osteoporotic fractures. In the present report, we developed a closed femur fracture pain model in the mouse where skeletal pain behaviors such as flinching and guarding of the fractured limb are reversed by 10 mg/kg morphine. Using this model we showed that the administration of a monoclonal antibody against nerve growth factor (anti-NGF) reduced fracture-induced pain-related behaviors by over 50%. Treatment with anti-NGF reduced c-Fos and dynorphin up-regulation in the spinal cord at day 2 post-fracture. However, anti-NGF treatment did not reduce p-ERK and c-Fos expression at 20 and 90 min, respectively, following fracture. This suggests NGF is involved in maintenance but not the acute generation of fracture pain. Anti-NGF therapy did not inhibit bone healing as measured by callus formation, bridging of the fracture site or mechanical strength of the bone. As the anti-NGF antibody does not appreciably cross the blood-brain barrier, the present data suggest that the anti-hyperalgesic action of anti-NGF therapy results from blockade of activation and/or sensitization of the CGRP/trkA positive fibers that normally constitute the majority of sensory fibers that innervate the bone. These results demonstrate that NGF plays a significant role in driving fracture pain and that NGF sequestering therapies may be efficacious in attenuating this pain.

AB - Current therapies to treat skeletal fracture pain are extremely limited. Some non-steroidal anti-inflammatory drugs have been shown to inhibit bone healing and opiates induce cognitive dysfunction and respiratory depression which are especially problematic in the elderly suffering from osteoporotic fractures. In the present report, we developed a closed femur fracture pain model in the mouse where skeletal pain behaviors such as flinching and guarding of the fractured limb are reversed by 10 mg/kg morphine. Using this model we showed that the administration of a monoclonal antibody against nerve growth factor (anti-NGF) reduced fracture-induced pain-related behaviors by over 50%. Treatment with anti-NGF reduced c-Fos and dynorphin up-regulation in the spinal cord at day 2 post-fracture. However, anti-NGF treatment did not reduce p-ERK and c-Fos expression at 20 and 90 min, respectively, following fracture. This suggests NGF is involved in maintenance but not the acute generation of fracture pain. Anti-NGF therapy did not inhibit bone healing as measured by callus formation, bridging of the fracture site or mechanical strength of the bone. As the anti-NGF antibody does not appreciably cross the blood-brain barrier, the present data suggest that the anti-hyperalgesic action of anti-NGF therapy results from blockade of activation and/or sensitization of the CGRP/trkA positive fibers that normally constitute the majority of sensory fibers that innervate the bone. These results demonstrate that NGF plays a significant role in driving fracture pain and that NGF sequestering therapies may be efficacious in attenuating this pain.

KW - Bone

KW - Monoclonal antibody therapy

KW - Nociception

KW - Non-malignant skeletal pain

KW - Periosteum

UR - http://www.scopus.com/inward/record.url?scp=36248975322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36248975322&partnerID=8YFLogxK

U2 - 10.1016/j.pain.2007.06.016

DO - 10.1016/j.pain.2007.06.016

M3 - Article

C2 - 17693023

AN - SCOPUS:36248975322

VL - 133

SP - 183

EP - 196

JO - Pain

JF - Pain

SN - 0304-3959

IS - 1-3

ER -